Rice Hall James & Associates LLC Purchases 9,889 Shares of Icon Plc $ICLR

Rice Hall James & Associates LLC grew its position in shares of Icon Plc (NASDAQ:ICLR) by 434.9% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 12,163 shares of the medical research company’s stock after buying an additional 9,889 shares during the quarter. Rice Hall James & Associates LLC’s holdings in Icon were worth $2,129,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds also recently modified their holdings of the company. Geneos Wealth Management Inc. boosted its holdings in shares of Icon by 11.5% in the 2nd quarter. Geneos Wealth Management Inc. now owns 541 shares of the medical research company’s stock worth $79,000 after acquiring an additional 56 shares in the last quarter. First National Bank Sioux Falls raised its position in Icon by 5.7% in the 2nd quarter. First National Bank Sioux Falls now owns 1,580 shares of the medical research company’s stock valued at $230,000 after purchasing an additional 85 shares during the last quarter. Mutual Advisors LLC boosted its stake in Icon by 3.6% in the second quarter. Mutual Advisors LLC now owns 2,698 shares of the medical research company’s stock worth $392,000 after purchasing an additional 93 shares in the last quarter. Private Trust Co. NA grew its holdings in shares of Icon by 200.0% during the third quarter. Private Trust Co. NA now owns 141 shares of the medical research company’s stock worth $25,000 after purchasing an additional 94 shares during the last quarter. Finally, Hunter Perkins Capital Management LLC grew its holdings in shares of Icon by 0.4% during the second quarter. Hunter Perkins Capital Management LLC now owns 22,399 shares of the medical research company’s stock worth $3,258,000 after purchasing an additional 97 shares during the last quarter. Institutional investors and hedge funds own 95.61% of the company’s stock.

Icon Stock Down 0.5%

Shares of NASDAQ ICLR opened at $182.84 on Friday. Icon Plc has a 1 year low of $125.10 and a 1 year high of $228.29. The firm’s 50-day moving average is $175.36 and its 200-day moving average is $169.89. The company has a current ratio of 1.06, a quick ratio of 1.06 and a debt-to-equity ratio of 0.31. The firm has a market capitalization of $14.77 billion, a PE ratio of 24.74, a price-to-earnings-growth ratio of 3.39 and a beta of 1.25.

Analyst Upgrades and Downgrades

A number of research analysts recently issued reports on the company. Robert W. Baird set a $220.00 price target on Icon in a report on Friday, October 24th. Cowen restated a “hold” rating on shares of Icon in a research report on Friday, October 24th. Bank of America downgraded shares of Icon from a “buy” rating to a “neutral” rating and set a $195.00 target price for the company. in a research note on Monday, December 15th. Barclays increased their price target on shares of Icon from $185.00 to $200.00 and gave the company an “equal weight” rating in a research note on Monday, December 15th. Finally, Leerink Partners set a $220.00 price target on shares of Icon in a report on Thursday, October 23rd. Two research analysts have rated the stock with a Strong Buy rating, eight have issued a Buy rating and eleven have issued a Hold rating to the company’s stock. According to MarketBeat, Icon presently has an average rating of “Moderate Buy” and an average price target of $205.31.

Icon Company Profile

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.